Michael J Kerin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9175241/publications.pdf

Version: 2024-02-01

339 papers 20,761 citations

14655 66 h-index 131 g-index

345 all docs 345 docs citations

345 times ranked

27921 citing authors

#	Article	IF	CITATIONS
1	Microwave Imaging in Breast Cancer – Results from the First-In-Human Clinical Investigation of the Wavelia System. Academic Radiology, 2022, 29, S211-S222.	2.5	38
2	Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery–A systematic review and meta-analysis. Breast, 2022, 61, 1-10.	2.2	22
3	Sentinel lymph node biopsy in patients with ductal carcinoma <i>in situ</i> : systematic review and meta-analysis. BJS Open, 2022, 6, .	1.7	9
4	Breast cancer recurrence: factors impacting occurrence and survival. Irish Journal of Medical Science, 2022, 191, 2501-2510.	1.5	12
5	Optimal localization strategies for non-palpable breast cancers –A network meta-analysis of randomized controlled trials. Breast, 2022, 62, 103-113.	2.2	12
6	Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis. BJS Open, 2022, 6, .	1.7	21
7	Overview of MicroRNA Expression in Predicting Response to Neoadjuvant Therapies in Human Epidermal Growth Receptor-2 Enriched Breast Cancer – A Systematic Review. Breast Cancer: Basic and Clinical Research, 2022, 16, 117822342210866.	1.1	3
8	The double agents in liquid biopsy: promoter and informant biomarkers of early metastases in breast cancer. Molecular Cancer, 2022, 21, 95.	19.2	11
9	Intraoperative recurrent laryngeal nerve monitoring versus visualisation alone - A systematic review and meta-analysis of randomized controlled trials. American Journal of Surgery, 2022, 224, 836-841.	1.8	15
10	Value of the 21-gene expression assay in predicting locoregional recurrence rates in estrogen receptor-positive breast cancer: a systematic review and network meta-analysis. Breast Cancer Research and Treatment, 2022, 193, 535-544.	2.5	7
11	Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review. BMC Cancer, 2022, 22, 396.	2.6	9
12	What Proportion of Systematic Reviews and Meta-Analyses Published in the Annals of Surgery Provide Definitive Conclusions—A Systematic Review and Bibliometric Analysis. Publications, 2022, 10, 19.	3.8	0
13	MicroRNA Expression Profiling Predicts Nodal Status and Disease Recurrence in Patients Treated with Curative Intent for Colorectal Cancer. Cancers, 2022, 14, 2109.	3.7	11
14	Relevance of the 21-gene expression assay in male breast cancer: A systematic review and meta-analysis. Breast, 2022, 64, 41-46.	2.2	3
15	Preoperative Breast Magnetic Resonance Imaging as a Predictor of Response to Neoadjuvant Chemotherapy. Breast Cancer: Basic and Clinical Research, 2022, 16, 117822342211035.	1.1	2
16	Evaluation of Human adipose-derived stromal cell behaviour following exposure to Tamoxifen. Tissue and Cell, 2022, , 101858.	2.2	0
17	A Novel Surrogate Nomogram Capable of Predicting OncotypeDX Recurrence Score©. Journal of Personalized Medicine, 2022, 12, 1117.	2.5	O
18	Neoadjuvant chemotherapy for luminal a breast cancer: Factors predictive of histopathologic response and oncologic outcome. American Journal of Surgery, 2021, 222, 368-376.	1.8	13

#	Article	IF	Citations
19	Targeting stromal cell Syndecanâ€2 reduces breast tumour growth, metastasis and limits immune evasion. International Journal of Cancer, 2021, 148, 1245-1259.	5.1	12
20	Use of Intraoperative Parathyroid Hormone in Minimally Invasive Parathyroidectomy for Primary Hyperparathyroidism. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 135.	2.2	25
21	Effect of Breast Cancer and Adjuvant Therapy on Adipose-Derived Stromal Cells: Implications for the Role of ADSCs in Regenerative Strategies for Breast Reconstruction. Stem Cell Reviews and Reports, 2021, 17, 523-538.	3.8	6
22	Evaluating the Clinical Utility of Routine Sentinel Lymph Node Biopsy and the Value of Adjuvant Chemotherapy in Elderly Patients Diagnosed With Oestrogen Receptor Positive, Clinically Node Negative Breast Cancer. Breast Cancer: Basic and Clinical Research, 2021, 15, 117822342110222.	1.1	3
23	Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women. New England Journal of Medicine, 2021, 384, 428-439.	27.0	532
24	Clinicopathological correlates, oncological impact, and validation of Oncotype DXâ,,¢ in a European Tertiary Referral Centre. Breast Journal, 2021, 27, 521-528.	1.0	22
25	FOXE1 polymorphism rs965513 predisposes to thyroid cancer in a European cohort. Endocrine Oncology, 2021, 1, 1-8.	0.4	0
26	Radioiodine Remnant Ablation for Differentiated Thyroid Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 544.	2.2	12
27	The Role of MicroRNA as Clinical Biomarkers for Breast Cancer Surgery and Treatment. International Journal of Molecular Sciences, 2021, 22, 8290.	4.1	29
28	Imprecise risk estimation of chemotherapy-related cardiotoxicity in HER2-positive breast cancer using the recently reported societal risk tools. Breast Cancer Research and Treatment, 2021, 190, 355-356.	2.5	0
29	Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. Cancers, 2021, 13, 4455.	3.7	73
30	The Wavelia Microwave Breast Imaging system–tumour discriminating features and their clinical usefulness. British Journal of Radiology, 2021, 94, 20210907.	2.2	10
31	OncotypeDX© Recurrence Score in BRCA mutation carriers: a systematic review and meta-analysis. European Journal of Cancer, 2021, 154, 209-216.	2.8	10
32	The use of radiomic analysis of magnetic resonance imaging in predicting distant metastases of rectal carcinoma following surgical resection: A systematic review and metaâ€analysis. Colorectal Disease, 2021, 23, 3065-3072.	1.4	9
33	Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer – A retrospective cohort study. Breast, 2021, 59, 67-75.	2.2	22
34	MicroRNAs in Molecular Classification and Pathogenesis of Breast Tumors. Cancers, 2021, 13, 5332.	3.7	24
35	MicroRNA Expression Profiles and Breast Cancer Chemotherapy. International Journal of Molecular Sciences, 2021, 22, 10812.	4.1	30
36	Radiomic differentiation of breast cancer molecular subtypes using pre-operative breast imaging – A systematic review and meta-analysis. European Journal of Radiology, 2021, 144, 109996.	2.6	26

#	Article	IF	CITATIONS
37	Automated Breast Lesion Detection and Characterization with the Wavelia Microwave Breast Imaging System: Methodological Proof-of-Concept on First-in-Human Patient Data. Applied Sciences (Switzerland), 2021, 11, 9998.	2.5	9
38	Relative and Absolute Expression Analysis of MicroRNAs Associated with Luminal A Breast Cancer– A Comparison. Pathology and Oncology Research, 2020, 26, 833-844.	1.9	19
39	Serial CRP levels following oesophagectomy: a marker for anastomotic dehiscence. Irish Journal of Medical Science, 2020, 189, 277-282.	1.5	3
40	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
41	Comment on "Implant-Based Breast Reconstruction With Acellular Dermal Matrix. Safety Data From an Open-Label, Multicenter, Randomized, Controlled Trial in the Setting of Breast Cancer Treatmentâ€. Annals of Surgery, 2020, 271, e106.	4.2	1
42	Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancers, 2020, 12, 1820.	3.7	31
43	C-Reactive Protein-Lymphocyte Ratio Identifies Patients at Low Risk for Major Morbidity after Oesophagogastric Resection for Cancer. Digestive Surgery, 2020, 37, 515-523.	1.2	14
44	The histopathological and molecular features of breast carcinoma with tumour budding—a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2020, 183, 503-514.	2.5	8
45	The Impact of Preoperative Breast Magnetic Resonance Imaging on Surgical Management in Symptomatic Patients With Invasive Lobular Carcinoma. Breast Cancer: Basic and Clinical Research, 2020, 14, 117822342094847.	1.1	7
46	A prospective feasibility study of MammoSite accelerated partial breast irradiation for early breast Cancer. Irish Journal of Medical Science, 2020, 189, 1203-1208.	1.5	2
47	Breast Cancer Detection—A Synopsis of Conventional Modalities and the Potential Role of Microwave Imaging. Diagnostics, 2020, 10, 103.	2.6	41
48	Investigating the Potential and Pitfalls of EV-Encapsulated MicroRNAs as Circulating Biomarkers of Breast Cancer. Cells, 2020, 9, 141.	4.1	24
49	Improving diagnostic accuracy in clinically ambiguous paediatric appendicitis: a retrospective review of ultrasound and pathology findings with focus on the non-visualised appendix. British Journal of Radiology, 2019, 92, 20180585.	2.2	6
50	Neoadjuvant chemoradiation and breast reconstruction: the potential for improved outcomes in the treatment of breast cancer. Irish Journal of Medical Science, 2019, 188, 75-83.	1.5	14
51	The changing cost of breast cancer care: lessons from a centralised modern cancer centre. Irish Journal of Medical Science, 2019, 188, 409-414.	1.5	5
52	Oncological Risk in Autologous Stem Cell Donation for Novel Tissue-Engineering Approaches to Postmastectomy Breast Regeneration. Breast Cancer: Basic and Clinical Research, 2019, 13, 117822341986489.	1.1	2
53	Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer. BMC Cancer, 2019, 19, 436.	2.6	68
54	A Review of the Impact of Neoadjuvant Chemotherapy on Breast Surgery Practice and Outcomes. Clinical Breast Cancer, 2019, 19, 377-382.	2.4	22

#	Article	IF	Citations
55	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	6.4	52
56	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	6.2	711
57	Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy. Breast Cancer Research and Treatment, 2019, 174, 1-13.	2.5	21
58	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 795-806.	1.9	81
59	Neoadjuvant radiotherapy for rectal cancer management. World Journal of Gastroenterology, 2019, 25, 4850-4869.	3.3	128
60	The role of stromal tumor infiltrating lymphocytes (sTILs) as a predictive biomarker for carboplatin-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) Journal of Clinical Oncology, 2019, 37, e12085-e12085.	1.6	0
61	Recent Advances and Future Directions in Postmastectomy Breast Reconstruction. Clinical Breast Cancer, 2018, 18, e571-e585.	2.4	23
62	Six-year review of traumatic brain injury in a regional trauma unit: demographics, contributing factors and service provision in Ireland. Brain Injury, 2018, 32, 900-906.	1.2	6
63	The clinical utility of pre-operative neutrophil-to-lymphocyte ratio as a predictor of outcomes in patients undergoing elective laparoscopic cholecystectomy. Irish Journal of Medical Science, 2018, 187, 755-760.	1.5	1
64	Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379. Oncogene, 2018, 37, 2137-2149.	5.9	150
65	Antibiotics Versus Surgical Therapy for Uncomplicated Appendicitis: Contrasting Interpretations of Data. Annals of Surgery, 2018, 268, e45-e46.	4.2	0
66	Re-Appraisal of Estrogen Receptor Negative/Progesterone Receptor Positive (ERâ^/PR+) Breast Cancer Phenotype: True Subtype or Technical Artefact? Pathology and Oncology Research, 2018, 24, 881-884.	1.9	24
67	Assessment of MicroRNA as Disease Predictors and Markers of Response in Rectal Cancer. Journal of the American College of Surgeons, 2018, 227, S60.	0.5	0
68	Differentiated Thyroid Cancer: How Do Current Practice Guidelines Affect Management?. European Thyroid Journal, 2018, 7, 319-326.	2.4	6
69	The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review. Breast, 2018, 42, 133-141.	2.2	4
70	Hydrogels in adipose tissue engineeringâ€"Potential application in postâ€mastectomy breast regeneration. Journal of Tissue Engineering and Regenerative Medicine, 2018, 12, 2234-2247.	2.7	27
71	Association between periâ€operative angiotensinâ€converting enzyme inhibitors and angiotensinâ€2 receptor blockers and acute kidney injury in major elective nonâ€cardiac surgery: a multicentre, prospective cohort study. Anaesthesia, 2018, 73, 1214-1222.	3.8	31
72	Body mass index and complications following major gastrointestinal surgery: a prospective, international cohort study and metaâ€analysis. Colorectal Disease, 2018, 20, O215-O225.	1.4	46

#	Article	IF	CITATIONS
73	The Impact of Surgical Complications on Cancer Recurrence Rates: A Literature Review. Oncology Research and Treatment, 2018, 41, 478-482.	1.2	25
74	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	21.4	184
75	The prognostic value of neutrophilâ€toâ€lymphocyte ratio in colorectal cancer: A systematic review. Journal of Surgical Oncology, 2017, 115, 470-479.	1.7	145
76	Teaching Radiology to Medical Studentsâ€"There Is a Need for Change to Better Prepare Students for Clinical Practice. Academic Radiology, 2017, 24, 506-513.	2.5	13
77	Screening of exosomal microRNAs from colorectal cancer cells. Cancer Biomarkers, 2017, 17, 427-435.	1.7	29
78	Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab. Breast Cancer Research and Treatment, 2017, 164, 221-229.	2.5	8
79	Amplification-free detection of microRNAs via a rapid microarray-based sandwich assay. Analytical and Bioanalytical Chemistry, 2017, 409, 3497-3505.	3.7	29
80	Investigating the association of rs2910164 with cancer predisposition in an Irish cohort. Endocrine Connections, 2017, 6, 614-624.	1.9	5
81	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	27.8	1,099
82	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
83	Locoregional Recurrence Following Breast Cancer Surgery in the Trastuzumab Era: A Systematic Review by Subtype. Annals of Surgical Oncology, 2017, 24, 3124-3132.	1.5	41
84	Adipose-Derived Stem Cells in Novel Approaches to Breast Reconstruction: Their Suitability for Tissue Engineering and Oncological Safety. Breast Cancer: Basic and Clinical Research, 2017, 11, 117822341772677.	1.1	38
85	A bibliometric analysis of the citation classics of acute appendicitis. Annals of Medicine and Surgery, 2017, 19, 45-50.	1.1	9
86	$$100\hat{l}^2$$ as a serum marker in endocrine resistant breast cancer. BMC Medicine, 2017, 15, 79.	5.5	20
87	Prospective comparison of outcome after treatment for triple-negative and non-triple-negative breast cancer. Journal of the Royal College of Surgeons of Edinburgh, 2017, 15, 272-277.	1.8	15
88	Circulating MicroRNAs in Cancer. Methods in Molecular Biology, 2017, 1509, 123-139.	0.9	18
89	Post-traumatic growth in breast cancer: how and when do distress and stress contribute?. Psycho-Oncology, 2017, 26, 967-974.	2.3	43
90	Follicular variant papillary thyroid carcinoma in Western Europe: A distinct clinical entity. European Journal of Surgical Oncology, 2017, 43, 2399-2400.	1.0	0

#	Article	IF	CITATIONS
91	Concordance of Final Histologic Analysis and Preoperative MRI Rectum: Does it Impact Individualized Treatment Plans and Patient Outcomes in Rectal Cancer?. Journal of the American College of Surgeons, 2017, 225, S38.	0.5	0
92	Utility of Neutrophil Lymphocyte Ratio as a Biomarker in Prediction of Prognostic Outcomes in Large-Bowel Malignancy. Journal of the American College of Surgeons, 2017, 225, S48-S49.	0.5	0
93	Circulating Nucleosomes and Nucleosome Modifications as Biomarkers in Cancer. Cancers, 2017, 9, 5.	3.7	99
94	Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer. Breast Cancer: Targets and Therapy, 2017, Volume 9, 393-400.	1.8	64
95	Impact of inducible nitric oxide synthase (iNOS) expression on triple negative breast cancer outcome and activation of EGFR and ERK signaling pathways. Oncotarget, 2017, 8, 80568-80588.	1.8	61
96	<i>PHIP</i> - a novel candidate breast cancer susceptibility locus on 6q14.1. Oncotarget, 2017, 8, 102769-102782.	1.8	9
97	Exosomeâ€encapsulated microRNAs as circulating biomarkers for breast cancer. International Journal of Cancer, 2016, 139, 1443-1448.	5.1	158
98	Second to Fourth Digit Ratios in Plastic Surgery. Plastic and Reconstructive Surgery - Global Open, 2016, 4, e602.	0.6	1
99	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174
100	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	5.0	31
101	Locoregional recurrence following breast cancer surgery in the trastuzumab era: A systematic review by subtype. European Journal of Surgical Oncology, 2016, 42, S9.	1.0	0
102	NCOA3 coactivator is a transcriptional target of XBP1 and regulates PERK–eIF2α–ATF4 signalling in breast cancer. Oncogene, 2016, 35, 5860-5871.	5.9	38
103	Genetic predisposition to ductal carcinoma in situ of the breast. Breast Cancer Research, 2016, 18, 22.	5.0	43
104	Targeting cancer using KAT inhibitors to mimic lethal knockouts. Biochemical Society Transactions, 2016, 44, 979-986.	3.4	52
105	Exploring circulating microâ€∢scp>RNA in the neoadjuvant treatment of breast cancer. International Journal of Cancer, 2016, 139, 12-22.	5.1	40
106	Recreating complex pathophysiologies in vitro with extracellular matrix surrogates for anticancer therapeutics screening. Drug Discovery Today, 2016, 21, 1521-1531.	6.4	28
107	FNAC and frozen section correlations with definitive histology in thyroid diseases. European Archives of Oto-Rhino-Laryngology, 2016, 273, 2181-2184.	1.6	8
108	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18

#	Article	IF	Citations
109	The future of UK/Irish surgery: A European solution. International Journal of Surgery, 2015, 23, 165-168.	2.7	O
110	Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 2015, 17, 58.	5.0	26
111	Effects of Age on the Detection and Management of Breast Cancer. Cancers, 2015, 7, 908-929.	3.7	263
112	A Circulating MicroRNA Signature as a Biomarker for Prostate Cancer in a High Risk Group. Journal of Clinical Medicine, 2015, 4, 1369-1379.	2.4	84
113	Awareness and Uptake of Family Screening in Patients Diagnosed with Colorectal Cancer at a Young Age. Gastroenterology Research and Practice, 2015, 2015, 1-4.	1.5	10
114	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, .	6.3	428
115	Current practice patterns of drain usage amongst UK and Irish surgeons performing bilateral breast reductions: Evidence down the drain. Journal of Plastic Surgery and Hand Surgery, 2015, 49, 363-366.	0.8	7
116	A metaâ€analysis to determine the oncological implications of conversion in laparoscopic colorectal cancer surgery. Colorectal Disease, 2015, 17, 482-490.	1.4	75
117	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Human Molecular Genetics, 2015, 24, 2966-2984.	2.9	40
118	The use of circulating microRNAs as diagnostic biomarkers in colorectal cancer. Cancer Biomarkers, 2015, 15, 103-113.	1.7	60
119	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. American Journal of Human Genetics, 2015, 96, 5-20.	6.2	76
120	Is there a role for locoregional surgery in stage IV breast cancer?. Breast, 2015, 24, 32-37.	2.2	11
121	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. Carcinogenesis, 2015, 36, 256-271.	2.8	14
122	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	21.4	513
123	Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer and Metastasis Reviews, 2015, 34, 145-155.	5.9	264
124	Identification of Novel Genetic Markers of Breast Cancer Survival. Journal of the National Cancer Institute, 2015, 107, .	6.3	56
125	A genetic variant at 12p11 significantly modifies breast cancer risk in a genetically homogenous island population. Breast Cancer Research and Treatment, 2015, 149, 41-47.	2.5	1
126	Symptomatic Breast Cancer Diagnosis and Multimodal Management in Women Aged 40 to 50 Years; Consequences of Current Mammographic Screening Programs. Clinical Breast Cancer, 2015, 15, e125-e130.	2.4	3

#	Article	IF	Citations
127	Aerosolized Intraperitoneal Local Anesthetic for Laparoscopic Surgery: A Randomized, Doubleâ€Blinded, Placeboâ€Controlled Trial. World Journal of Surgery, 2015, 39, 1681-1689.	1.6	14
128	An Evaluation of the Use of Deliberate Practice and Simulation to Train Interns in Requesting Blood Products. Simulation in Healthcare, 2015, 10, 92-97.	1.2	11
129	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. Journal of the National Cancer Institute, 2015, 107, djv219.	6.3	99
130	Estrogen withdrawal, increased breast cancer risk and the KRAS-variant. Cell Cycle, 2015, 14, 2091-2099.	2.6	11
131	MicroRNA-10a is reduced in breast cancer and regulated in part through retinoic acid. BMC Cancer, 2015, 15, 345.	2.6	59
132	Targeted resequencing of the microRNAome and 3′UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer. Oncogene, 2015, 34, 2125-2137.	5.9	24
133	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Human Molecular Genetics, 2015, 24, 285-298.	2.9	38
134	The Oncologic Safety and Practicality of Breast Conservation Surgery in Large Breast Tumors 5ÂCentimeters or More. Clinical Breast Cancer, 2015, 15, e47-e53.	2.4	5
135	Cross Platform Standardisation of an Experimental Pipeline for Use in the Identification of Dysregulated Human Circulating MiRNAs. PLoS ONE, 2015, 10, e0137389.	2.5	7
136	Evolution of a research field—a micro (RNA) example. PeerJ, 2015, 3, e829.	2.0	15
137	MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973.	2.5	49
138	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. PLoS Genetics, 2014, 10, e1004285.	3.5	39
139	The acquisition and retention of urinary catheterisation skills using surgical simulator devices: teaching method or student traits. BMC Medical Education, 2014, 14, 264.	2.4	13
140	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2014, 23, 6096-6111.	2.9	53
141	Experience of Breast Cancer. Cancer Nursing, 2014, 37, E21-E30.	1.5	35
142	Plastic Surgery and the Breast. Plastic and Reconstructive Surgery - Global Open, 2014, 2, e251.	0.6	16
143	The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre. European Journal of Cancer, 2014, 50, 2763-2770.	2.8	71
144	Lobular Breast Cancer in a CDH1 Splice Site Mutation Carrier: Case Report and Review of the Literature. Clinical Breast Cancer, 2014, 14, e47-e51.	2.4	11

#	Article	IF	CITATIONS
145	Familial breast cancer genetic testing in the West of Ireland. Irish Journal of Medical Science, 2014, 183, 199-206.	1.5	3
146	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. Human Molecular Genetics, 2014, 23, 1934-1946.	2.9	32
147	Interns and their smartphones: use for clinical practice. Postgraduate Medical Journal, 2014, 90, 75-79.	1.8	65
148	Assessing the Impact of Neoadjuvant Chemotherapy on the Management of the Breast and Axilla in Breast Cancer. Clinical Breast Cancer, 2014, 14, 20-25.	2.4	17
149	FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. British Journal of Cancer, 2014, 110, 1088-1100.	6.4	21
150	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nature Communications, 2014, 5, 4999.	12.8	105
151	A germline mutation in the BRCA13'UTR predicts Stage IV breast cancer. BMC Cancer, 2014, 14, 421.	2.6	14
152	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Human Molecular Genetics, 2014, 23, 6034-6046.	2.9	12
153	Hands of a surgeon: Second to fourth digit ratios in the surgical profession. Personality and Individual Differences, 2014, 68, 28-31.	2.9	1
154	Total systemic ropivacaine concentrations following aerosolized intraperitoneal delivery using the AeroSurge. Journal of Clinical Anesthesia, 2014, 26, 18-24.	1.6	10
155	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Research, 2014, 16, R51.	5.0	14
156	Identification and Validation of Oncologic miRNA Biomarkers for Luminal A-like Breast Cancer. PLoS ONE, 2014, 9, e87032.	2.5	93
157	Impact of Tumour Epithelial Subtype on Circulating microRNAs in Breast Cancer Patients. PLoS ONE, 2014, 9, e90605.	2.5	14
158	Global stress predicts both positive and negative emotional adjustment at diagnosis and postâ€surgery in women with breast cancer. Psycho-Oncology, 2013, 22, 177-185.	2.3	36
159	A review of expression profiling of circulating microRNAs in men with prostate cancer. BJU International, 2013, 111, 17-21.	2.5	29
160	mRNA/miRNA correlations in colorectal cancer: novel mechanisms in cancer initiation and progression. International Journal of Colorectal Disease, 2013, 28, 1031-1034.	2.2	4
161	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. American Journal of Human Genetics, 2013, 93, 1046-1060.	6.2	98
162	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493

#	Article	IF	Citations
163	Gastrointestinal complications of pelvic radiotherapy: medical and surgical management strategies. Current Problems in Surgery, 2013, 50, 395-407.	1.1	14
164	Increasing Reporting of Adverse Events to Improve the Educational Value of the Morbidity and Mortality Conference. Journal of the American College of Surgeons, 2013, 216, 50-56.	0.5	34
165	Impact of Mesenchymal Stem Cell secreted PAI-1 on colon cancer cell migration and proliferation. Biochemical and Biophysical Research Communications, 2013, 435, 574-579.	2.1	42
166	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. American Journal of Human Genetics, 2013, 92, 489-503.	6.2	201
167	Enlarging neck masses in the elderly – Histological and surgical considerations. International Journal of Surgery Case Reports, 2013, 4, 378-381.	0.6	2
168	Water-clear cell adenoma: A rare form of hyperparathyroidism. International Journal of Surgery Case Reports, 2013, 4, 911-913.	0.6	14
169	Assessing the impact of an ageing population on complication rates and in-patient length of stay. International Journal of Surgery, 2013, 11, 872-875.	2.7	32
170	miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy. International Journal of Colorectal Disease, 2013, 28, 247-260.	2.2	65
171	Genome-wide association studies identify four ER negative–specific breast cancer risk loci. Nature Genetics, 2013, 45, 392-398.	21.4	374
172	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	21.4	960
173	Career choices of today's medical students: where does surgery rank?. Irish Journal of Medical Science, 2013, 182, 337-343.	1.5	23
174	miRNAs as colorectal cancer biomarkers: current progress and future challenges. Colorectal Cancer, 2013, 2, 419-427.	0.8	0
175	Surgeon and Breast Unit Volume-Outcome Relationships in Breast Cancer Surgery and Treatment. Annals of Surgery, 2013, 258, 808-814.	4.2	45
176	Nippleâ€sparing mastectomy: can preoperative biopsy findings predict retroareolar margin involvement?. Histopathology, 2013, 63, 143-146.	2.9	4
177	The Prognostic Significance of Nodal Ratio on Breast Cancer Recurrence and its Potential for Incorporation in a New Prognostic Index. Breast Journal, 2013, 19, 388-393.	1.0	10
178	Cognitiveâ€behavioural stress management enhances adjustment in women with breast cancer. British Journal of Health Psychology, 2013, 18, 623-641.	3.5	55
179	"Excuse Me:―Teaching Interns to Speak Up. Joint Commission Journal on Quality and Patient Safety, 2013, 39, 426-431.	0.7	35
180	miR-379 Regulates Cyclin B1 Expression and Is Decreased in Breast Cancer. PLoS ONE, 2013, 8, e68753.	2.5	75

#	Article	IF	CITATIONS
181	Identification and Validation of miRNAs as Endogenous Controls for RQ-PCR in Blood Specimens for Breast Cancer Studies. PLoS ONE, 2013, 8, e83718.	2.5	94
182	Isolation of Secreted microRNAs (miRNAs) from Cell-conditioned Media. MicroRNA (Shariqah, United) Tj ETQq0	0 0 _{f.g} BT /0	Overlock 10 Tf
183	Clinical applications of gene expression in colorectal cancer. Journal of Gastrointestinal Oncology, 2013, 4, 144-57.	1.4	28
184	Mismatch repair protein expression in colorectal cancer. Journal of Gastrointestinal Oncology, 2013, 4, 397-408.	1.4	42
185	An assessment of stress in Irish interns. Medical Teacher, 2012, 34, 424-424.	1.8	4
186	19p13.1 Is a Triple-Negative–Specific Breast Cancer Susceptibility Locus. Cancer Research, 2012, 72, 1795-1803.	0.9	100
187	MicroRNA-9 Inhibition of Cell Proliferation and Identification of Novel miR-9 Targets by Transcriptome Profiling in Breast Cancer Cells. Journal of Biological Chemistry, 2012, 287, 29516-29528.	3.4	170
188	Surgent University. Surgical Innovation, 2012, 19, 200-204.	0.9	3
189	The impact of international guidelines on breast cancer management. Breast Cancer Management, 2012, 1, 73-82.	0.2	O
190	Surgical Mentors and Role Models: Prevalence, Importance and Associated Traits. Journal of Surgical Education, 2012, 69, 633-637.	2.5	47
191	MicroRNA expression in colorectal cancer. Cancer Biomarkers, 2012, 11, 239-243.	1.7	14
192	Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nature Genetics, 2012, 44, 312-318.	21.4	256
193	A Unique Cause of a Rare Disorder, Unilateral Macromastia Due to Lymphangiomatosis of the Breast: A Case Report. Breast Journal, 2012, 18, 367-370.	1.0	6
194	9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1783-1791.	2.5	17
195	Role models and mentors in surgery. American Journal of Surgery, 2012, 204, 256-261.	1.8	114
196	Regulatory interplay between miR-21, JAG1 and 17beta-estradiol (E2) in breast cancer cells. Biochemical and Biophysical Research Communications, 2012, 423, 234-239.	2.1	22
197	West of Ireland facial injury study. Part 1. British Journal of Oral and Maxillofacial Surgery, 2012, 50, 631-635.	0.8	14
198	West of Ireland facial injury study. Part 2. British Journal of Oral and Maxillofacial Surgery, 2012, 50, e99-e103.	0.8	15

#	Article	IF	Citations
199	Changing practices in the surgical management of hyperparathyroidism – A 10-year review. Journal of the Royal College of Surgeons of Edinburgh, 2012, 10, 314-320.	1.8	4
200	Smart phone apps: Smart patients, steer clear. Patient Education and Counseling, 2012, 89, 360-361.	2.2	28
201	CYP3A Variation, Premenopausal Estrone Levels, and Breast Cancer Risk. Journal of the National Cancer Institute, 2012, 104, 657-669.	6.3	30
202	The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer. PLoS ONE, 2012, 7, e37891.	2.5	30
203	Relationship between Circulating and Tissue microRNAs in a Murine Model of Breast Cancer. PLoS ONE, 2012, 7, e50459.	2.5	44
204	Expression levels of HER2/neu and those of collocated genes at 17q12-21, in breast cancer. Oncology Reports, 2012, 28, 365-9.	2.6	8
205	11q13 is a susceptibility locus for hormone receptor positive breast cancer. Human Mutation, 2012, 33, 1123-1132.	2.5	35
206	Mesenchymal stem cells in the colorectal tumor microenvironment: Recent progress and implications. International Journal of Cancer, 2012, 131, 1-7.	5.1	46
207	Systemic mirnas as potential biomarkers for malignancy. International Journal of Cancer, 2012, 131, 2215-2222.	5.1	37
208	Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Research and Treatment, 2012, 133, 831-841.	2.5	333
209	Influence of stromal–epithelial interactions on breast cancer in vitro and in vivo. Breast Cancer Research and Treatment, 2012, 131, 401-411.	2.5	20
210	An unusual presentation of a calcified thyroid gland. BMJ Case Reports, 2012, 2012, bcr2012007844-bcr2012007844.	0.5	2
211	Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS ONE, 2012, 7, e42380.	2.5	51
212	Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2222-2231.	2.5	27
213	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. Journal of the National Cancer Institute, 2011, 103, 250-263.	6.3	596
214	Oral cavity examination: beyond the core curriculum?. British Journal of Oral and Maxillofacial Surgery, 2011, 49, 640-642.	0.8	21
215	A $3\hat{a}\in^2$ -untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncology, The, 2011, 12, 377-386.	10.7	130
216	Association between KRAS rs61764370 and triple-negative breast cancerâ€"a false positive? â€" Authors' reply. Lancet Oncology, The, 2011, 12, 724.	10.7	1

#	Article	IF	Citations
217	Circulating microRNAs: promising breast cancer Biomarkers. Breast Cancer Research, 2011, 13, 402; author reply 403.	5.0	35
218	The Sodium Iodide Symporter (NIS) and Potential Regulators in Normal, Benign and Malignant Human Breast Tissue. PLoS ONE, 2011, 6, e16023.	2.5	29
219	Interns' attitudes to IV cannulation: a KAP study. British Journal of Nursing, 2011, 20, S15-S20.	0.7	10
220	Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics. Breast Cancer Research and Treatment, 2011, 126, 131-140.	2.5	130
221	The h index and the identification of global benchmarks for breast cancer research output. Breast Cancer Research and Treatment, 2011, 127, 845-851.	2.5	28
222	The Therapeutic Potential of MicroRNAs: Disease Modulators and Drug Targets. Pharmaceutical Research, 2011, 28, 3016-3029.	3.5	67
223	MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. International Journal of Colorectal Disease, 2011, 26, 1415-1422.	2.2	96
224	A study of pre-operative type and screen in breast surgery: improved efficiency and cost saving. Irish Journal of Medical Science, 2011, 180, 513-516.	1.5	10
225	Complementary and alternative medicine use in oncology: A questionnaire survey of patients and health care professionals. BMC Cancer, 2011, 11, 196.	2.6	79
226	Younger age as a prognostic indicator in breast cancer: A cohort study. BMC Cancer, 2011, 11, 383.	2.6	67
227	The effect of breast cancer awareness month on internet search activity - a comparison with awareness campaigns for lung and prostate cancer. BMC Cancer, 2011, 11, 442.	2.6	90
228	Mesenchymal Stem Cell-Mediated Delivery of the Sodium Iodide Symporter Supports Radionuclide Imaging and Treatment of Breast Cancer. Stem Cells, 2011, 29, 1149-1157.	3.2	76
229	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortiumâ€. Human Molecular Genetics, 2011, 20, 4693-4706.	2.9	71
230	TOP2A Amplification in the Absence of That of HER-2/neu: Toward Individualization of Chemotherapeutic Practice in Breast Cancer. Oncologist, 2011, 16, 949-955.	3.7	10
231	Interns' attitudes to IV cannulation: a KAP study. British Journal of Nursing, 2011, 20, S15-S20.	0.7	8
232	Electronic follow-up of facial lacerations in the emergency department. Journal of Telemedicine and Telecare, 2011, 17, 133-136.	2.7	16
233	Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. British Journal of Cancer, 2011, 105, 1934-1939.	6.4	4
234	Differential miRNA Expression in Omental Adipose Tissue and in the Circulation of Obese Patients Identifies Novel Metabolic Biomarkers. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E846-E850.	3.6	190

#	Article	IF	Citations
235	Mesenchymal Stem Cells and Cancer: Tumor-Specific Delivery Vehicles or Therapeutic Targets?. Human Gene Therapy, 2010, 21, 1506-1512.	2.7	39
236	The TGFBR1*6A/9A polymorphism is not associated with differential risk of breast cancer. Breast Cancer Research and Treatment, 2010, 119, 437-442.	2.5	18
237	Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort. Breast Cancer Research and Treatment, 2010, 121, 203-210.	2.5	32
238	Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Research and Treatment, 2010, 124, 317-326.	2.5	270
239	MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer. BMC Cancer, 2010, 10, 173.	2.6	193
240	Dysregulated miR-183 inhibits migration in breast cancer cells. BMC Cancer, 2010, 10, 502.	2.6	121
241	Identification of endogenous control genes for normalisation of real-time quantitative PCR data in colorectal cancer. BMC Molecular Biology, 2010, $11,12$.	3.0	73
242	Description and validation of a novel programme for theatre-based surgical education. Medical Education, 2010, 44, 1129-1130.	2.1	1
243	Role of microRNAs in obesity and the metabolic syndrome. Obesity Reviews, 2010, 11, 354-361.	6.5	185
244	Systemic <i>miRNA-195</i> Differentiates Breast Cancer from Other Malignancies and Is a Potential Biomarker for Detecting Noninvasive and Early Stage Disease. Oncologist, 2010, 15, 673-682.	3.7	295
245	Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer. Annals of Surgery, 2010, 251, 499-505.	4.2	600
246	Circulating miRNA Signatures: Promising Prognostic Tools for Cancer. Journal of Clinical Oncology, 2010, 28, e573-e574.	1.6	62
247	Systemic microRNAs: novel biomarkers for colorectal and other cancers?. Gut, 2010, 59, 1002-1004.	12.1	9
248	Factors influencing medical students and junior doctors in choosing a career in surgery. Journal of the Royal College of Surgeons of Edinburgh, 2010, 8, 187-191.	1.8	60
249	Topoisomerase 2 Alpha and the Case for Individualized Breast Cancer Therapy. Annals of Surgical Oncology, 2010, 17, 1392-1397.	1.5	12
250	MiRNAs as biomarkers and therapeutic targets in cancer. Current Opinion in Pharmacology, 2010, 10, 543-550.	3.5	222
251	Magnetic resonance imaging of the breast: Recommendations from the EUSOMA working group. European Journal of Cancer, 2010, 46, 1296-1316.	2.8	813
252	Breast cancer research output, 1945-2008: a bibliometric and density-equalizing analysis. Breast Cancer Research, 2010, 12, R108.	5.0	64

#	Article	IF	Citations
253	17q12-21 – The pursuit of targeted therapy in breast cancer. Cancer Treatment Reviews, 2010, 36, 224-229.	7.7	25
254	Advances in mesenchymal stem cell-mediated gene therapy for cancer. Stem Cell Research and Therapy, 2010, 1, 25.	5.5	97
255	Metastatic breast disease: an all too common cause of back pain. BMJ Case Reports, 2010, 2010, bcr1020092388-bcr1020092388.	0.5	1
256	Representation of Cancer in the Medical Literature - A Bibliometric Analysis. PLoS ONE, 2010, 5, e13902.	2.5	50
257	Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. International Journal of Cancer, 2009, 124, 326-332.	5.1	116
258	Postmenopausal hormone therapy and prevalent round screening mammography. International Journal of Cancer, 2009, 124, 1490-1491.	5.1	1
259	Systemic chemokine levels in breast cancer patients and their relationship with circulating menstrual hormones. Breast Cancer Research and Treatment, 2009, 115, 279-287.	2.5	13
260	Low penetrance breast cancer predisposition SNPs are site specific. Breast Cancer Research and Treatment, 2009, 117, 151-159.	2.5	37
261	Interactions between the estrogen receptor, its cofactors and microRNAs in breast cancer. Breast Cancer Research and Treatment, 2009, 116, 425-432.	2.5	23
262	A rare case of arterial thrombosis in a 37-year-old male with Factor V Leiden mutation. Irish Journal of Medical Science, 2009, 178, 363-366.	1.5	3
263	Evolution of breast cancer management in Ireland: a decade of change. BMC Surgery, 2009, 9, 15.	1.3	11
264	Breast cancer subtypes and molecular biomarkers. Diagnostic Histopathology, 2009, 15, 485-489.	0.4	11
265	Graves' ophthalmopathy: The case for thyroid surgery. Journal of the Royal College of Surgeons of Edinburgh, 2009, 7, 290-296.	1.8	11
266	MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neureceptor status in breast cancer. Breast Cancer Research, 2009, 11, R27.	5.0	375
267	Progesterone receptor B (PRB) promoter hypermethylation in sporadic breast cancer. Breast Cancer Research and Treatment, 2008, 111, 45-53.	2.5	17
268	General paediatric surgery in Ireland: a crisis in evolution. Irish Journal of Medical Science, 2008, 177, 9-10.	1.5	0
269	Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Molecular Biology, 2008, 9, 76.	3.0	229
270	The effect of menopause and hysterectomy on systemic vascular endothelial growth factor in women undergoing surgery for breast cancer. BMC Cancer, 2008, 8, 279.	2.6	9

#	Article	IF	Citations
271	A pilot project of european working time directive compliant rosters in a university teaching hospital. Journal of the Royal College of Surgeons of Edinburgh, 2008, 6, 88-93.	1.8	33
272	MicroRNAs as Prognostic Indicators and Therapeutic Targets: Potential Effect on Breast Cancer Management. Clinical Cancer Research, 2008, 14, 360-365.	7.0	150
273	Estrogen Induces Repression of the <i>Breast Cancer and Salivary Gland Expression</i> Gene in an Estrogen Receptor α–Dependent Manner. Cancer Research, 2008, 68, 106-114.	0.9	23
274	Growth arrest-specific gene 6 expression in human breast cancer. British Journal of Cancer, 2008, 98, 1141-1146.	6.4	48
275	Digital rectal examination: national survey of undergraduate medical training in Ireland. Postgraduate Medical Journal, 2007, 83, 599-601.	1.8	29
276	Monocyte Chemotactic Protein-1 Secreted by Primary Breast Tumors Stimulates Migration of Mesenchymal Stem Cells. Clinical Cancer Research, 2007, 13, 5020-5027.	7.0	399
277	Role of sentinel lymph node biopsy in high-risk ductal carcinoma in situ patients. American Journal of Surgery, 2007, 194, 172-175.	1.8	41
278	Development of a molecular methodology to quantify Staphylococcus epidermidis in surgical wash-out samples from prosthetic joint replacement surgery. European Journal of Orthopaedic Surgery and Traumatology, 2007, , 1.	1.4	7
279	Evaluation and validation of candidate endogenous control genes for real-time quantitative PCR studies of breast cancer. BMC Molecular Biology, 2007, 8, 107.	3.0	80
280	Radial scars/complex sclerosing lesions and malignancy in a screening programme: incidence and histological features revisited. Histopathology, 2007, 50, 607-614.	2.9	69
281	Development of a molecular methodology to quantify Staphylococcus epidermidis in surgical washout samples from prosthetic joint replacement surgery. European Journal of Orthopaedic Surgery and Traumatology, 2007, 17, 449-456.	1.4	9
282	A case of bilateral breast cancer with Peutz–Jeghers syndrome. European Journal of Surgical Oncology, 2006, 32, 121-122.	1.0	5
283	Gain of imprinting of SLC22A18 sense and antisense transcripts in human breast cancer. Genomics, 2006, 88, 12-17.	2.9	34
284	Inhibition of the Stress Response to Breast Cancer Surgery by Regional Anesthesia and Analgesia Does Not Affect Vascular Endothelial Growth Factor and Prostaglandin E2. Anesthesia and Analgesia, 2005, 100, 244-249.	2,2	123
285	Sentinel lymph node biopsy. BMJ: British Medical Journal, 2004, 328, 1330-1331.	2.3	43
286	Minimally invasive parathyroidectomy with operative ultrasound localization of the adenoma. Surgical Endoscopy and Other Interventional Techniques, 2004, 18, 1097-8.	2.4	16
287	Erratum to "The value of axillary lymphadenectomy―[European Journal of Surgical Oncology 29 (2003) 701–702]. European Journal of Surgical Oncology, 2004, 30, 90.	1.0	0
288	Paravertebral Analgesia with Levobupivacaine Increases Postoperative Flap Tissue Oxygen Tension after Immediate Latissimus Dorsi Breast Reconstruction Compared with Intravenous Opioid Analgesia. Anesthesiology, 2004, 100, 375-380.	2.5	64

#	Article	IF	Citations
289	Sentinel lymph node biopsy: Authors' reply. BMJ: British Medical Journal, 2004, 329, 170.4-171.	2.3	O
290	Malignant phaeochromocytoma metastasising to the breast. Irish Journal of Medical Science, 2003, 172, 41-42.	1.5	4
291	The value of axillary lymphadenectomy. European Journal of Surgical Oncology, 2003, 29, 701-702.	1.0	3
292	Intracellular Flow Cytometric Analysis of Primary Cultured Breast Tumor Cells. Cancer Investigation, 2002, 20, 340-347.	1.3	6
293	Breast reconstruction in the United Kingdom and Ireland. British Journal of Surgery, 2002, 89, 335-340.	0.3	60
294	The missing mammographic abnormality. British Journal of Surgery, 2002, 86, 851-852.	0.3	1
295	Prognostic significance of oestrogen receptor \hat{l}^2 in breast cancer. British Journal of Surgery, 2002, 87, 405-409.	0.3	56
296	Soluble FLT-1 is detectable in the sera of colorectal and breast cancer patients. Anticancer Research, 2002, 22, 1877-80.	1.1	22
297	Genetic changes in breast cancer detected by comparative genomic hybridisation. International Journal of Cancer, 2000, 86, 494-500.	5.1	69
298	Gilmore's Groin Repair in Athletes. Journal of Orthopaedic and Sports Physical Therapy, 2000, 30, 329-332.	3.5	71
299	Genetic changes in breast cancer detected by comparative genomic hybridisation., 2000, 86, 494.		1
300	Dynamic Contrast Enhanced Magnetic Resonance Imaging of the Breast Is Superior to Triple Assessment for the Pre-Operative Detection of Multifocal Breast Cancer. Annals of Surgical Oncology, 1999, 6, 599-603.	1.5	108
301	Genetic changes associated with telomerase activity in breast cancer. , 1999, 84, 516-520.		28
302	Prospective Comparison of Standard Triple Assessment and Dynamic Magnetic Resonance Imaging of the Breast for the Evaluation of Symptomatic Breast Lesions. Annals of Surgery, 1999, 230, 680.	4.2	28
303	Vascular endothelial growth factor in premenopausal women-indicator of the best time for breast cancer surgery?. British Journal of Cancer, 1998, 78, 1203-1207.	6.4	57
304	Short-term primary culture of epithelial cells derived from human breast tumours. British Journal of Cancer, 1998, 78, 1421-1429.	6.4	88
305	Prognostic factors: guidelines for investigation design and state of the art analytical methods. Surgical Oncology, 1998, 7, 71-76.	1.6	17
306	Routine screening for local recurrence following breast-conserving therapy for cancer with dynamic contrast-enhanced magnetic resonance imaging of the breast. Annals of Surgical Oncology, 1998, 5, 265-270.	1.5	63

#	Article	IF	CITATIONS
307	Editorial. Irish Journal of Medical Science, 1998, 167, 70-71.	1.5	0
308	Magnetic-resonance imaging for breast cancer. Lancet, The, 1998, 351, 1661-1662.	13.7	4
309	Mammographic assessment of the symptomatic nonsuspicious breast. American Journal of Surgery, 1997, 173, 181-184.	1.8	7
310	Argon-enhanced cutting and coagulation confers advantages over conventional electrocautery for mastectomy. European Journal of Surgical Oncology, 1996, 22, 571-573.	1.0	18
311	Laparoscopic oophorectomy: a prospective evaluation in pre-menopausal breast cancer with particular reference to incidence and severity of menopausal symptoms. European Journal of Surgical Oncology, 1996, 22, 491-493.	1.0	1
312	Synchronous metastatic breast cancer in a husband and wife. Irish Journal of Medical Science, 1996, 165, 50-50.	1.5	3
313	Royal Academy of Medicine in Ireland Section of Surgery. Irish Journal of Medical Science, 1996, 165, 63-67.	1.5	O
314	Oesophago-vascular fistulae secondary to benign peptic ulcer disease: A rare cause of fatal haemorrhage. European Journal of Vascular and Endovascular Surgery, 1995, 10, 370-371.	1.5	0
315	Meralgia paraesthetica following laparoscopic inguinal hernia repair. Surgical Endoscopy and Other Interventional Techniques, 1995, 9, 76-78.	2.4	63
316	An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma. British Journal of Cancer, 1995, 71, 1288-1291.	6.4	47
317	Unilateral breast masses in men over 40: A diagnostic dilemma. American Journal of Surgery, 1995, 170, 24-26.	1.8	39
318	Linkage analysis and the susceptibility gene (BRCA-1) in familial breast cancer. European Journal of Surgical Oncology, 1995, 21, 240-241.	1.0	11
319	Royal Academy of Medicine in Ireland section of surgery. Irish Journal of Medical Science, 1994, 163, 475-477.	1.5	0
320	Bile duct injuries in open and laparoscopic cholecystectomy: Apples and oranges. Irish Journal of Medical Science, 1994, 163, 1-3.	1.5	0
321	Irish society for gastroenterology. Irish Journal of Medical Science, 1994, 163, 37-47.	1.5	0
322	Seventeenth sir peter freyer memorial lecture and surgical symposium. Irish Journal of Medical Science, 1994, 163, 68.	1.5	0
323	Irish Society of Gastroenterology. Irish Journal of Medical Science, 1994, 163, 577-590.	1.5	0
324	Waterford surgical october club meeting and surgical section, royal academy of medicine in Ireland. Irish Journal of Medical Science, 1994, 163, 533-538.	1.5	0

#	Article	IF	CITATIONS
325	Seventeenth Sir Peter Freyer memorial lecture and surgical symposium. Irish Journal of Medical Science, 1994, 163, 139-167.	1.5	O
326	19th Sir peter freyer memorial lecture and surgical symposium 16th and 17th September 1994. Irish Journal of Medical Science, 1994, 163, 417-446.	1.5	0
327	Radionuclide limb blood flow measurements to resolve diagnostic problems in vascular surgery. Nuclear Medicine Communications, 1994, 15, 148-151.	1.1	6
328	In situ ESWL for ureteric calculi: The optimum treatment?. Irish Journal of Medical Science, 1993, 162, 348-350.	1.5	5
329	Irish society of gastroenterology. Irish Journal of Medical Science, 1993, 162, 362-375.	1.5	0
330	Irish society of gastroenterology. Irish Journal of Medical Science, 1992, 161, 600-619.	1.5	0
331	Laparoscopic common bile duct exploration. Irish Journal of Medical Science, 1992, 161, 1-2.	1.5	4
332	A prospective and randomised study comparing the incidence of infusion phlebitis during continuous and cyclic peripheral parenteral nutrition. Clinical Nutrition, 1991, 10, 315-319.	5.0	39
333	Irish association for cancer research. Irish Journal of Medical Science, 1991, 160, 116-126.	1.5	0
334	Irish society of gastroenterology. Irish Journal of Medical Science, 1991, 160, 70-78.	1.5	0
335	Irish society of gastroenterology. Irish Journal of Medical Science, 1991, 160, 79-88.	1.5	0
336	Endoscopic management of common duct stones with laparoscopic cholecystectomy. Irish Journal of Medical Science, 1991, 160, 265-267.	1.5	16
337	Royal academy of medicine in ireland section of biological sciences. Irish Journal of Medical Science, 1990, 159, 23-37.	1.5	0
338	Royal Academy of Medicine in Ireland Section of Sugery. Irish Journal of Medical Science, 1989, 158, 234-238.	1.5	0
339	Restriction fragment length polymorphism in malignant breast tumours with the 3′-end of the human progesterone receptor cDNA. Biochemical Society Transactions, 1989, 17, 408-408.	3.4	0